Since DOACs are a recommended therapy for non-valvular AF patients with coronary risk factors, such as diabetes, and that diabetes, chronic kidney disease, and AF are interrelated with each other [11,12,13,14,15,16,17,18,19,20,36], we examined here the effects of an inhibitor of factor Xa apixaban, one of the DOACs on experimental diabetic nephropathy. The gene discussed is F10; the disease is diabetic kidney disease.